RS
STLN

R Squared’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

R Squared’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.3K Sell
11,482
-4,871
-30% -$20.5K 0.03% 439
2026
Q1 		$50.2K Buy
16,353
+4,891
+43% +$15K 0.03% 419
2025
Q4 		$40.8K Buy
+11,462
New +$42.5K 0.02% 470

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

R Squared's STLN Position: Q2 2026 in Review

R Squared reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 30% in Q2 2026, selling an estimated $20.5K and leaving 11,482 shares worth $62.3K. The position accounts for 0.03% of the portfolio, ranked #439.

R Squared first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • R Squared held 11,482 shares of Starling Oncology Institute, Inc. Common Stock worth $62.3K as of Q2 2026.
  • R Squared sold 4,871 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $20.5K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.03% of R Squared's portfolio in Q2 2026, its #439 holding.
  • R Squared first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.